The Impact of the COVID-19 Pandemic on Outcomes in Acute Pancreatitis: A Propensity Score Matched Study Comparing before and during the Pandemic
Abstract
:1. Introduction
2. Materials and Methods
2.1. Inclusion Criteria
2.2. Exclusion Criteria
2.3. Study Design
2.4. Statistical Analysis
3. Results
3.1. Demographic, Clinical and Biological Data of AP Patients from the Pre-COVID-19 vs. during-COVID-19 Group
3.2. Demographic and Biological Data of Pre-COVID-19 AP Patients vs. COVID-19 AP Patients
3.3. Demographic and Biological Data of AP Patients in the during-COVID-19 Period vs. AP Patients with COVID-19
3.4. Comparison of Patients Discharged Alive and Those Who Died in the Pre-COVID-19 Group
3.5. Comparison of Patients Discharged Alive and Those Who Died in the during-COVID-19 Group
3.6. Comparison of Patients with AP and COVID-19 Disease Discharged Alive and Those Who Died
4. Discussion
Study Limitation
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Petrov, M.S.; Yadav, D. Global epidemiology and holistic prevention of pancreatitis. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 175–184. [Google Scholar] [CrossRef]
- Zheng, Z.; Ding, Y.-X.; Qu, Y.-X.; Cao, F.; Li, F. A narrative review of acutepancreatitis and its diagnosis, pathogenetic mecha-nism, and management. Ann.Transl. Med. 2021, 9, 69. [Google Scholar] [CrossRef]
- Boxhoorn, L.; Voermans, R.P.; Bouwense, S.A.; Treese, C. Acute pancreatitis. Lancet 2020, 396, 726–734. [Google Scholar] [CrossRef] [PubMed]
- Roberts, S.E.; Morrison-Rees, S.; John, A.; Williams, J.G.; Brown, T.H.; Samuel, D.G. The incidence and aetiology of acutepancreatitis across Europe. Pancreatology 2017, 17, 155–165. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cho, J.; Petrov, M.S. Pancreatitis, Pancreatic Cancer, and Their Metabolic Sequelae: Projected Burden to 2050. Clin. Transl. Gastroenterol. 2020, 11, e00251. [Google Scholar] [CrossRef] [PubMed]
- Banks, P.A.; Bollen, T.L.; Dervenis, C.; Johnson, C.D.; Sarr, M.G.; Vege, S.S. Classification of acute pancreatitis—2012: Revision of the Atlanta classification and definitions by international consensus. Gut 2013, 62, 102–111. [Google Scholar] [CrossRef] [PubMed]
- Chan, K.S.; Shelat, V.G. Diagnosis, severity stratification and management of adult acute pancreatitis–current evidence and controversies. World J. Gastrointest. Surg. 2022, 14, 1179–1197. [Google Scholar] [CrossRef]
- van Dijk, S.M.; Hallensleben, N.D.L.; van Santvoort, H.C.; Fockens, P.; van Goor, H.; Bruno, M.J.; Besselink, M.G. Acute pancreatitis:recent advances through randomised trials. Gut 2017, 66, 2024–2032. [Google Scholar] [CrossRef]
- Karimi, S.E.; Ahmadi, S.; Azar, N.S. Inequities as a Social Determinant of Health: Responsibility in Paying Attention to the Poor and Vulnerable at Risk of COVID-19. J. Public Health Res. 2021, 10, 1904. [Google Scholar] [CrossRef]
- Volintiru, C.; Gherghina, S. We are in this together: Stakeholder cooperation during COVID-19 in Romania. Eur. Politi Sci. 2022, 1, 1–11. [Google Scholar] [CrossRef]
- Mărcău, F.-C.; Purec, S.; Niculescu, G. Study on the Refusal of Vaccination against COVID-19 in Romania. Vaccines 2022, 10, 261. [Google Scholar] [CrossRef]
- Mărcău, F.C.; Peptan, C.; Nedelcuță, R.M.; Băleanu, V.D.; Băleanu, A.R.; Niculescu, B. Parental COVID-19 Vaccine Hesitancy for Children in Romania: National Survey. Vaccines 2022, 10, 547. [Google Scholar] [CrossRef]
- Cheeyandira, A. The effects of COVID-19 pandemic on the provision of urgent surgery: A perspective from the USA. J. Surg. Case Rep. 2020, 2020, rjaa109. [Google Scholar] [CrossRef] [PubMed]
- Wongtanasarasin, W.; Srisawang, T.; Yothiya, W.; Phinyo, P. Impact of national lockdown towards emergency department visits and admission rates during the COVID-19 pandemic in Thailand: A hospital-based study. Emerg. Med. Australas. 2020, 33, 316–323. [Google Scholar] [CrossRef] [PubMed]
- Pandanaboyana, S.; Moir, J.; Leeds, J.S.; Oppong, K.; Kanwar, A.; Marzouk, A. SARS-CoV-2 infection in acute pancreatitis increases disease severity and 30-day mortality: COVID PAN collaborative study. Gut 2021, 70, 1061–1069. [Google Scholar] [CrossRef] [PubMed]
- Dirweesh, A.; Li, Y.; Trikudanathan, G.; Mallery, J.S.; Freeman, M.L.; Amateau, S.K. Clinical Outcomes of Acute Pancreatitis in Patients With Coronavirus Disease 2019. Gastroenterology 2020, 159, 1972–1974. [Google Scholar] [CrossRef]
- Samanta, J.; Mahapatra, S.J.; Kumar, N.; Elhence, A.; Dhar, J.; Gupta, A.; Dhooria, A.; Bhalla, A.; Prasad, M.; Das, A.; et al. Virus related acute pancreatitis and virus superinfection in the ‘Dual disease’ model of acute pancreatitis and SARS-Co-V2 infection: A multicentre prospective study. Pancreatology 2022, 22, 339–347. [Google Scholar] [CrossRef]
- Colvin, S.D.; Smith, E.N.; Morgan, D.E.; Porter, K.K. Acute pancreatitis: An update on the revised Atlanta classification. Abdom. Imaging 2019, 45, 1222–1231. [Google Scholar] [CrossRef]
- Benjamini, Y.; Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J. Royal Statistical Soc. Ser. B Methodol. 1995, 57, 289–300. [Google Scholar] [CrossRef]
- Inamdar, S.; Benias, P.C.; Liu, Y.; Sejpal, D.V.; Satapathy, S.K.; Trindade, A.J. The Northwell COVID-19 Research Consortium. Prevalence, Risk Factors, and Outcomes of Hospitalized Patients with Coronavirus Disease 2019 Presenting as Acute Pancreatitis. Gastroenterology 2020, 159, 2226–2228.e2. [Google Scholar] [CrossRef]
- Shushtari, Z.J.; Salimi, Y.; Ahmadi, S.; Rajabi-Gilan, N.; Shirazikhah, M.; Biglarian, A.; Almasi, A.; Gharehghani, M.A.M. Social determinants of adherence to COVID-19 preventive guidelines: A comprehensive review. Osong Public Health Res. Perspect. 2021, 12, 346–360. [Google Scholar] [CrossRef]
- De Rosa, S.; Spaccarotella, C.; Basso, C.; Calabrò, M.P.; Curcio, A.; Filardi, P.P.; Mancone, M.; Mercuro, G.; Muscoli, S.; Nodari, S.; et al. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Eur. Heart J. 2020, 41, 2083–2088. [Google Scholar] [CrossRef] [PubMed]
- Hübner, M.; Zingg, T.; Martin, D.; Eckert, P.; Demartines, N. Surgery for non-COVID-19 patients during the pandemic. PLoS ONE 2020, 15, e0241331. [Google Scholar] [CrossRef] [PubMed]
- Martellucci, J.; Damigella, A.; Bergamini, C.; Alemanno, G.; Pantalone, D.; Coratti, A.; Muiesan, P.; Cianchi, F.; Prosperi, P. Emer-gency surgery in the time of Coronavirus: The pandemic effect. Minerva Chir. 2020, 76, 382–387. [Google Scholar]
- Zintsmaster, M.P.; Myers, D.T. Patients avoided important care during the early weeks of the coronavirus pandemic: Divertic-ulitis patients were more likely to present with an abscess on CT. Emerg. Radiol. 2021, 28, 279–282. [Google Scholar] [CrossRef]
- Rosa, F.; Covino, M.; Sabia, L.; Quero, G.; Fiorillo, C.; Cozza, V.; Sganga, G.; Gasbarrini, A.; Franceschi, F.; Alfieri, S. Surgical emer-gencies during SARS-CoV-2 pandemic lockdown: What happened? Eur. Rev. Med. Pharmacol. Sci. 2020, 24, 11919–11925. [Google Scholar] [PubMed]
- Hartnett, K.P.; Kite-Powell, A.; DeVies, J.; Coletta, M.A.; Boehmer, T.K.; Adjemian, J.; Gundlapalli, A.V. National Syndromic Surveillance Program Community of Practice. Impact of the COVID-19 Pandemic on Emergency Department Visits—United States, 1 January 2019–30 May 2020. MMWR Morb Mortal Wkly Rep. 2020, 69, 699c704. [Google Scholar] [CrossRef]
- COVIDSurg Collaborative. Elective surgery cancellations due to the COVID-19 pandemic: Global predictive modelling to inform surgical recovery plans. Br. J. Surg. 2020, 107, 1440–1449. [Google Scholar] [CrossRef]
- Cuadros, D.F.; Branscum, A.J.; Mukandavire, Z.; Miller, F.D.; MacKinnon, N. Dynamics of the COVID-19 epidemic in urban and rural areas in the United States. Ann. Epidemiol. 2021, 59, 16–20. [Google Scholar] [CrossRef]
- Olariu, T.R.; Craciun, A.C.; Vlad, D.C.; Dumitrascu, V.; Marincu, I.; Lupu, M.A. SARS-CoV-2 Seroprevalence in Western Romania, March to June 2021. Medicina 2022, 58, 35. [Google Scholar] [CrossRef]
- Mueller, J.T.; McConnell, K.; Burow, P.B.; Pofahl, K.; Merdjanoff, A.A.; Farrell, J. Impacts of the COVID-19 pandemic on rural America. Proc. Natl. Acad. Sci. USA 2020, 118, 2019378118. [Google Scholar] [CrossRef] [PubMed]
- Huang, Q.; Jackson, S.; Derakhshan, S.; Lee, L.; Pham, E.; Jackson, A.; Cutter, S.L. Urban-rural differences in COVID-19 exposures and outcomes in the South: A preliminary analysis of South Carolina. PLoS ONE 2021, 16, e0246548. [Google Scholar] [CrossRef] [PubMed]
- Qian, G.-Q.; Yang, N.-B.; Ding, F.; Ma, A.H.Y.; Wang, Z.-Y.; Shen, Y.-F.; Shi, C.-W.; Lian, X.; Chu, J.-G.; Chen, L.; et al. Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series. QJM Int. J. Med. 2020, 113, 474–481. [Google Scholar] [CrossRef] [Green Version]
- Xu, X.-W.; Wu, X.-X.; Jiang, X.-G.; Xu, K.-J.; Ying, L.-J.; Ma, C.-L.; Li, S.-B.; Wang, H.-Y.; Zhang, S.; Gao, H.-N.; et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: Retrospective case series. BMJ 2020, 368, m606. [Google Scholar] [CrossRef] [Green Version]
- Wu, J.; Liu, J.; Zhao, X.; Liu, C.; Wang, W.; Wang, D.; Xu, W.; Zhang, C.; Yu, J.; Jiang, B.; et al. Clinical Characteristics of Imported Cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: A Multicenter Descriptive Study. Clin. Infect. Dis. 2020, 71, 706–712. [Google Scholar] [CrossRef]
- Tabiei, S.; Farajzadeh, Z.; Eizadpanah, A. Self-medication with drug amongst university students of Birjand. Mod. Care J. 2012, 9, 4. [Google Scholar]
- Mulki, R.; Shah, R.; Qayed, E. Early vs late endoscopic retrograde cholangiopancreatography in patients with acute cholangitis: A nationwide analysis. World J. Gastrointest. Endosc. 2019, 11, 41–53. [Google Scholar] [CrossRef] [PubMed]
- Cobre, A.D.F.; Böger, B.; Fachi, M.M.; Vilhena, R.D.O.; Domingos, E.L.; Tonin, F.S.; Pontarolo, R. Risk factors associated with delay in diagnosis and mortality in patients with COVID-19 in the city of Rio de Janeiro, Brazil. Cien Saude Colet. 2020, 25, 4131–4140. [Google Scholar] [CrossRef]
- Güngör, B.; Cağlayan, K.; Polat, C.; Seren, D.; Erzurumlu, K.; Malazgirt, Z. The predictivity of serum biochemical markers in acute biliary pancreatitis. ISRN Gastroenterol. 2011, 2011, 279607. [Google Scholar] [CrossRef] [Green Version]
- Liu, W.; Du, J.J.; Li, Z.H.; Zhang, X.Y.; Zuo, H.D. Liver injury associated with acute pancreatitis: The current status of clinical evaluation and involved mechanisms. World J. Clin. Cases 2021, 9, 10418–10429. [Google Scholar] [CrossRef]
- Sarges, P.; Steinberg, J.M.; Lewis, J.H. Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature. Drug Saf. 2016, 39, 801–821. [Google Scholar] [CrossRef] [PubMed]
- Kazemioula, G.; Golestani, S.; Alavi, S.M.A.; Taheri, F.; Gheshlagh RGLotfalizadeh, M.H. Prevalence of self-medication during COVID-19 pandemic: A systematic review and meta-analysis. Front. Public Health 2022, 10, 1041695. [Google Scholar] [CrossRef] [PubMed]
- Brooks, S.K.; Webster, R.K.; Smith, L.E.; Woodland, L.; Wessely, S.; Greenberg, N.; Rubin, G.J. The psychological impact of quarantine and how to reduce it: Rapid review of the evidence. Lancet 2020, 395, 912–920. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Steptoe, A.; O’Donnell, K.; Badrick, E.; Kumari, M.; Marmot, M. Neuroendocrine and Inflammatory Factors Associated with Positive Affect in Healthy Men and Women: The Whitehall II Study. Am. J. Epidemiol. 2007, 167, 96–102. [Google Scholar] [CrossRef]
- Butterworth, R.F. Hepatic encephalopathy: A central neuroinflammatory disorder? Hepatology 2011, 53, 1372–1376. [Google Scholar] [CrossRef]
- Loria, P.; Carulli, L.; Bertolotti, M.; Lonardo, A. Endocrine and liver interaction: The role of endocrine pathways in NASH. Nat. Rev. Gastroenterol. Hepatol. 2009, 6, 236–247. [Google Scholar] [CrossRef]
- Clay, J.M.; Parker, M.O. Alcohol use and misuse during the COVID-19 pandemic: A potential public health crisis? Lancet Public Health 2020, 5, e259. [Google Scholar] [CrossRef]
- Calina, D.; Hartung, T.; Mardare, I.; Mitroi, M.; Poulas, K.; Tsatsakis, A.; Rogoveanu, I.; Docea, A.O. COVID-19 pandemic and alcohol consumption: Impacts and interconnections. Toxicol. Rep. 2021, 8, 529–535. [Google Scholar] [CrossRef]
- Pollard, M.S.; Tucker, J.S.; Green, H.D. Changes in Adult Alcohol Use and Consequences During the COVID-19 Pandemic in the US. JAMA Netw. Open 2020, 3, e2022942. [Google Scholar] [CrossRef]
- Naveau, S.; Raynard, B.; Ratziu, V.; Abella, A.; Imbert–Bismut, F.; Messous, D.; Beuzen, F.; Capron, F.; Thabut, D.; Munteanu, M.; et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin. Gastroenterol. Hepatol. 2005, 3, 167–174. [Google Scholar] [CrossRef]
- Liu, S.-Y.; Tsai, I.-T.; Hsu, Y.-C. Alcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives. Int. J. Mol. Sci. 2021, 22, 5170. [Google Scholar] [CrossRef] [PubMed]
- Zhao, X.; Lei, Z.; Gao, F.; ** and health anxiety. Appetite 2021, 161, 105082. [Google Scholar] [CrossRef]
- Leung, P.S.; Chan, Y.C.; Chvanov, M.; Huang, W.; **, T.; Wen, L.; Armstrong, J.; Elliot, V.; Alston, B.; Burdyga, A.; et al. Role of Oxidative Stress in Pancreatic Inflammation. Antioxid. Redox Signal. 2009, 11, 135–166. [Google Scholar] [CrossRef]
- Memba, R.; Duggan, S.N.; Ni Chonchubhair, H.M.; Griffin, O.M.; Bashir, Y.; O’Connor, D.B.; Murphy, A.; McMahon, J.; Volcov, Y.; Ryan, B.; et al. The potential role of gut microbiota in pancreatic disease: A systematic review. Pancreatology 2017, 17, 867–874. [Google Scholar] [CrossRef]
- Tan, C.; Ling, Z.; Huang, Y.; Cao, Y.; Liu, Q.; Cai, T.; Yuan, H.; Liu, C.; Li, Y.; Xu, K. Dysbiosis of Intestinal Microbiota Associated With Inflammation Involved in the Progression of Acute Pancreatitis. Pancreas 2015, 44, 868–875. [Google Scholar] [CrossRef]
- Huizar, M.I.; Arena, R.; Laddu, D.R. The global food syndemic: The impact of food insecurity, Malnutrition and obesity on the healthspan amid the COVID-19 pandemic. Prog. Cardiovasc. Dis. 2020, 64, 105–107. [Google Scholar] [CrossRef] [PubMed]
- Schaible, U.E.; Kaufmann, S.H.E. Malnutrition and Infection: Complex Mechanisms and Global Impacts. PLoS Med. 2007, 4, e115. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Correia, M.I.T.D.; Waitzberg, D.L. The impact of malnutrition on morbidity, mortality, length of hospital stay and costs evaluated through a multivariate model analysis. Clin. Nutr. 2003, 22, 235–239. [Google Scholar] [CrossRef] [PubMed]
Primay Results | Secondary Results |
---|---|
| Is there an increased risk of death for patients with AP during the COVID-19 pandemic and, if so, can this be quantified? Did COVID-19 infection have an impact on the clinical outcomes and survival rate of patients with AP? Can COVID-19 infection exacerbate the risk of death in patients with AP and, if so, can this be numerically evaluated? |
Variable | AP Pre-COVID-19 a (n = 56) | AP during-COVID-19 b (n = 56) | AP with COVID-19 c (n = 28) | p a,b | p a–c | p b,c |
---|---|---|---|---|---|---|
Area | 0.705 † | 0.277 † | 0.434 † | |||
Urban | 27 (8.2%) | 25 (46.6%) | 10 (35.7%) | |||
Rural | 29 (51.8%) | 31 (55.4%) | 18 (64.3%) | |||
Age | 49 (38–63) | 50 (44–64) | 49 (41–63) | 0.305 | 0.887 | 0.475 |
Sex | 1 † | 1 † | 1 † | |||
M | 38 (67.9%) | 38 (67.9%) | 19 (67.9%) | |||
W | 18 (32.1%) | 18 (32.1%) | 9 (32.1%) | |||
AP Severity | 1 † | 1 † | 1 † | |||
Mild | 6 (10.7%) | 6 (10.7%) | 3 (10.7%) | |||
Moderately_s | 26 (46.4%) | 26 (46.4%) | 13 (46.4%) | |||
Severe | 24 (42.9%) | 24 (42.9%) | 12 (42.9%) | |||
Hours onset | 24 (12–35) | 36 (24–48) | 24 (12–72) | 0.002 * | 0.161 | 0.785 |
Hospital stay | 12 (8–19) | 9 (7–12) | 9 (7–15) | 0.029 * | 0.110 | 0.696 |
Palpation | 0.064 † | 0.008 *† | 0.462 † | |||
Pain | 30 (53.6%) | 20 (35.7%) | 7 (25.0%) | |||
Tenderness | 14 (25.0%) | 13 (23.2%) | 6 (21.4%) | |||
Guarding | 12 (21.4%) | 23 (41.1%) | 15 (53.6%) | |||
HTN | 0.403 † | 0.306 † | 0.685 † | |||
Yes | 21 (37.5) | 13 (23.2%) | 6 (21.4%) | |||
No | 35 (62.5%) | 43 (76.8%) | 22 (78.6%) | |||
Diabetes | 0.809 † | 0.848 † | 0.723 † | |||
Yes | 11 (19.6%) | 10 (17.9%) | 6 (21.4%) | |||
No | 45 (80.4%) | 46 (82.1%) | 22 (78.6%) | |||
Complications | 0.547 † | 0.746 † | 0.774 † | |||
Yes | 20 (32.15%) | 17 (30.4%) | 9 (32.1%) | |||
No | 36 (64.3%) | 39 (69.6%) | 19 (67.9%) | |||
MSOF | 0.468 † | 0.179 † | 0.380 † | |||
Yes | 8 (14.3%) | 12 (21.4%) | 8 (28.6%) | |||
No | 48 (85.7%) | 44 (78.6%) | 20 (71.4%) | |||
HAPS | 0.541 † | 0.317 † | 0.642 † | |||
0 | 26 (46.4%) | 21 (37.5%) | 8 (28.6%) | |||
1 | 22 (39.3%) | 23 (41.1%) | 12 (42.9%) | |||
2 | 5 (8.9%) | 5 (8.9%) | 5 (17.9%) | |||
3 | 3 (5.4%) | 7 (12.5%) | 3 (10.7%) | |||
Surgery | 0.508 † | 0.264 † | 0.514 † | |||
Yes | 6 (10.7%) | 4 (7.1%) | 1 (3.6%) | |||
No | 50 (89.3%) | 52 (92.9%) | 27 (96.4%) | |||
Mortality | 0.031 *† | <0.001 *† | 0.028 *† | |||
Yes | 4 (7.1%) | 12 (21.4%) | 12 (42.9%) | |||
No | 52 (92.9%) | 44 (78.6%) | 16 (57.1%) |
Variable | AP Pre-COVID-19 a (n = 56) | AP during-COVID-19 b (n = 56) | AP with COVID-19 c (n = 28) | p a,b | p a–c | p b,c |
---|---|---|---|---|---|---|
Leucocytes (×103/µL) | 11.9 (7.2–16.3) | 9.2 (7.6–13.3) | 12.6 (9.4–19.8) | 0.192 | 0.044 * | 0.002 * |
Neutrophile (×103/µL) | 8.2 (11.9–13.8) | 8.0 (5.5–10.2) | 9.1 (6.5–16.1) | 0.658 | 0.133 | 0.021 * |
Lymphocyte (×103/µL) | 1.5 (0.9–2.0) | 1.4 (1.0–2.0) | 2 (1.0–2.5) | 0.658 | 0.220 | 0.074 |
Monocyte (×103/µL) | 0.8 (0.5–1.2) | 0.6 (0.5–0.8) | 0.9 (0.5–1.4) | 0.085 | 0.287 | 0.015 * |
Platelets (×103/µL) | 195.9 (176.4–271.5) | 183.0 (148.0–284.8) | 237.0 (189.0–253.0) | 0.254 | 0.453 | 0.323 |
Hb (g/dL) | 13.6 (12.1–14.5) | 12.5 (11.7–14.5) | 14.0 (10.8–15.9) | 0.073 | 0.790 | 0.414 |
Ht (%) | 38.6 (36.4–44.6) | 38.2 (34.5–43.6) | 35.6 (33.3–43.4) | 0.159 | 0.178 | 0.857 |
RDW | 12.8 (11.1–14.4) | 13.2 (12.4–14.4) | 14 (13.7–14.7) | 0.311 | 0.001 * | 0.004 * |
MCV (fL) | 88.5 (85.2–95.8) | 93.6 (88.7–99.0) | 95.6 (88.4–102.6) | 0.002 * | 0.002 * | 0.362 |
Proteins (g/dL) | 6.5 (6.0–7.2) | 6.0 (5.4–7.0) | 6.4 (5.1–7.3) | 0.001 * | 0.342 | 0.543 |
Amylase (U/L) | 320 (81.3–495.5) | 248.0 (172.0–515.0) | 323.5 (186.0–1114.3) | 1 | 0.288 | 0.384 |
Na (mmol/L) | 134 (129.0–140.0) | 137.6 (131.0–140.0) | 136.5 (132.0–140.0) | 0.218 | 0.565 | 0.610 |
K (mmol/L) | 4.5 (3.8–5.0) | 3.9 (3.7–4.8) | 4.1 (3.5–4.8) | 0.064 | 0.207 | 0.917 |
Glycemia (mg/dL) | 136 (85.0–158.0) | 111 (95.0–212.0) | 99 (93.0–134.8) | 0.691 | 0.102 | 0.035 * |
AST (U/L) | 42 (26.3–110.0) | 88 (37.5–184.0) | 58.0 (33.0–117.0) | 0.019 * | 0.314 | 0.333 |
ALT (U/L) | 48.5 (20.0–172.0) | 87 (52.5–226.5) | 58.0 (24.0–159.0) | 0.001 * | 0.393 | 0.144 |
Urea (mg/dL) | 33 (30.0–49.0) | 32 (24.3–69.0) | 35.5 (26.0–59.0) | 0.550 | 0.932 | 0.930 |
Creatinine (mg/dL) | 0.9 (0.7–1.1) | 0.7 (0.67–1.0) | 0.7 (0.6–1.4) | 0.022 * | 0.305 | 0.887 |
INR | 1.1 (1.1–1.3) | 1.2 (1.0–1.4) | 1.0 (1.0–1.1) | 0.554 | 0.000 * | 0.002 * |
NLR | 6.5 (3.0–12.9) | 5.8 (3.4–12.2) | 5.3 (3.3–11.2) | 0.852 | 0.776 | 0.955 |
IIC | 7.7 (3.2–15.7) | 7.6 (3.9–17.4) | 9.9 (4.2–18.7) | 0.376 | 0.352 | 0.556 |
MCVL | 63.6 (41.5–98.8) | 61.2 (46.3–105.5) | 43.4 (36.9–101.3) | 0.306 | 0.494 | 0.051 |
AP Pre-COVID-19 | AP during-COVID-19 | AP with COVID-19 | |||||||
---|---|---|---|---|---|---|---|---|---|
Variable | Alive (n = 52) | Deceased (n = 4) | p | Alive (n = 44) | Deceased (n = 12) | p | Alive (n = 16) | Deceased (n = 12) | p |
Area | 0.266 † | 0.282 † | 0.069 † | ||||||
Urban | 24 (46.2%) | 3 (75%) | 18 (40.9%) | 7 (58.3%) | 8 (50%) | 1 (8.3%) | |||
Rural | 48 (53.8%) | 1 (25%) | 26 (59.1%) | 5 (41.7%) | 8 (50%) | 11 (91.7%) | |||
Age | 46.5 (35–61) | 57 (51–63) | 0.251 | 47 (44–62) | 61 (44–64) | 0.179 | 45.50 (37–61) | 57.5 (42–77) | 0.377 |
Sex | 0.153 † | 0.382 † | 0.129 † | ||||||
M | 34 (65.4%) | 4 (100%) | 29 (65.9%) | 9 (75%) | 9 (56.2%) | 10 (83.3%) | |||
W | 18 (34.6%) | 0 | 15 (34.1%) | 3 (25%) | 7 (43.8%) | 2 (16.7%) | |||
AP Severity | 0.057 † | 0.001 *† | 0.000 *† | ||||||
Mild | 6 (11.5%) | 0 | 6 (13.6%) | 0 | 3 (18.8%) | 0 | |||
Moderately_s | 26 (50%) | 0 | 25 (56.8%) | 1 (8.3%) | 13 (81.2%) | 0 | |||
Severe | 20 (38.5%) | 4 (100%) | 13 (29.5%) | 11 (91.7%) | 0 | 12 (100%) | |||
Hours onset | 24 (12–30) | 39 (6.00–72) | 0.844 | 24 (24–48) | 48 (36–66) | 0.004 * | 12 (12–24) | 71.5 (39–72) | 0.002 * |
Hospital stay | 12 (8–19) | 13.50 (5–22) | 0.798 | 9 (6–10) | 12.5 (9–25) | 0.004 * | 8 (7–10) | 15 (14–32) | 0.003 * |
Palpation | 0.081 † | 0.002 *† | 0.001 *† | ||||||
Pain | 30 (57.7%) | 0 | 20 (45.5%) | 0 | 7 (43.8%) | 0 | |||
Tenderness | 12 (23.1%) | 2 (50%) | 11 (25.0%) | 2 (16.7%) | 0 | 6 (50%) | |||
Guarding | 10 (19.2%) | 2 (50%) | 13 (29.5%) | 10 (83.3%) | 9 (56.2%) | 6 (50%) | |||
HTN | 0.751 † | 1 † | 0.184 † | ||||||
Yes | 17 (32.7%) | 1 (25%) | 11 (25.0%) | 3 (25.0%) | 2 (12.5%) | 4 (33.3%) | |||
No | 35 (67.3%) | 3 (75%) | 33 (75.0%) | 9 (75.0%) | 14 (87.5%) | 8 (66.7%) | |||
Diabetes | 0.113 † | 0.903 † | 0.690 † | ||||||
Yes | 9 (17.3%) | 2 (50%) | 8 (18.2%) | 2 (16.7%) | 3 (18.8%) | 3 (25%) | |||
No | 43 (82.7%) | 2 (50%) | 36 (81.8%) | 10 (83.3%) | 13 (81.2%) | 9 (75%) | |||
Complications | 0.536 † | <0.001 *† | 0.005 *† | ||||||
Yes | 18 (34.6%) | 2 (50%) | 7 (15.9%) | 10 (83.3%) | 2 (12.5%) | 8 (66.7%) | |||
No | 34 (65.4%) | 2 (50%) | 37 (84.1%) | 2 (16.7%) | 14 (87.5%) | 4 (33.3%) | |||
MSOF | 0.001 *† | 0.000 *† | <0.001 *† | ||||||
Yes | 6 (11.5%) | 3 (75%) | 2 (4.5%) | 10 (83.3%) | 2 (12.5%) | 8 (66.7%) | |||
No | 46 (88.5%) | 1 (25%) | 42 (95.5%) | 2 (16.7%) | 14 (87.5%) | 4 (33.3%) | |||
HAPS | 0.000 *† | 0.020 *† | 0.103 † | ||||||
0 | 26 (50%) | 0 | 20 (45.5%) | 1 (8.3%) | 7 (43.8%) | 1 (8.3%) | |||
1 | 20 (38.5%) | 2 (50%) | 18 (40.9%) | 5 (41.7%) | 5 (31.2%) | 7 (58.4%) | |||
2 | 5 (9.6%) | 0 | 3 (6.8%) | 2 (16.7%) | 1 (6.2%) | 4 (33.3%) | |||
3 | 1 (1.9%) | 2 (50%) | 3 (6.8%) | 4 (33.3%) | 3 (18.8%) | 0 | |||
Surgery | 0.472 † | 0.278 † | 0.240 † | ||||||
Yes | 6 (11.5%) | 0 | 4 (9.1%) | 0 | 0 | 1 (8.3%) | |||
No | 46 (88.5%) | 4 (100%) | 40 (90.9%) | 12 (100%) | 16 (100%) | 11 (91.7%) |
AP Pre-COVID-19 | AP during-COVID-19 | AP with COVID-19 | |||||||
---|---|---|---|---|---|---|---|---|---|
Variable | Alive N (%) | Deceased N (%) | p | Alive N (%) | Deceased N (%) | p | Alive N (%) | Deceased N (%) | p |
Leucocyte (×103/µL) | 11.7 (7.2–16.3) | 21.4 (16.5–26.0) | 0.005 * | 9.2 (7.5–13.3) | 7.8 (7.1–19.9) | 0.952 | 16.4 (10.2–19.8) | 10.7 (7.7–31.1) | 0.456 |
Neutrophil (×103/µL) | 7.0 (5.2–12.9) | 18.5 (14.0–22.9) | 0.005 * | 8.2 (4.5–10.2) | 6.1 (5.7–17.6) | 0.535 | 9.1 (6.7–16.1) | 9.2 (5.7–27.1) | 0.544 |
Lymfocyte (×103/µL) | 1.6 (0.9–2.2) | 1.1 (1.0–1.1) | 0.372 | 1.6 (1.1–2.0) | 1.0 (0.7–1.0) | 0.000 * | 2.4 (2.0–16.1) | 1.1 (0.9–1.3) | 0.018 * |
Monocyte (×103/µL) | 0.7 (0.5–1.1) | 1.5 (1.5–1.6) | 0.006 * | 0.6 (0.4–0.8) | 0.7 (0.5–1.2) | 0.810 | 1.0 (0.6–1.7) | 0.8 (0.3–1.3) | 0.124 |
Platelet (×103/µL) | 193.6 (170.7–222.8) | 377 (362.0–391.3) | 0.005 * | 191.0 (148.0–284.0) | 148.0 (95.5–299.4) | 0.105 | 237.0 (189.8–287.2) | 207.0 (51.9–249.3) | 0.167 |
Hb (g/dL) | 13.7 (12.2–14.5) | 12.4 (11.3–13.4) | 0.143 | 12.4 (11.7–14.3) | 9.0 (8.5–17.1) | 0.222 | 14.0 (11.2–16.0) | 13.2 (10.1–15.6) | 0.208 |
Ht (%) | 38.6 (36.9–45.0) | 37.1 (34.3–39.8) | 0.339 | 38.6 (35.6–43.3) | 26.4 (25.7–44.3) | 0.271 | 35.6 (34.2–43.4) | 38.7 (29.5–44.2) | 0.327 |
RDW | 12.8 (11.9–13.7) | 14.7 (13.9–23.8) | 0.022 * | 12.5 (11.7–14.3) | 14.9 (12.4–15.6) | 0.254 | 13.8 (13.7–14.0) | 14.7 (14.2–15.2) | 0.004 * |
MCV | 89.1 (85.4–96.3) | 82.4 (79.9–84.9) | 0.011 * | 89.9 (88.3–97.3) | 105.0 (100.1–107.2) | 0.000 * | 90.3 (88.1–93.8) | 102.6 (98.6–102.8) | 0.000 * |
Proteins (g/dL) | 6.6 (6.1–7.2) | 6.1 (5.7–6.5) | 0.097 | 6.0 (5.5–7.3) | 6.3 (5.4–5.6) | 0.457 | 6.9 (6.4–7.4) | 5.1 (4.5–5.12) | 0.000 * |
Amylase (U/L) | 319 (80.5–492.5) | 480.5 (456.0–503.9) | 0.161 | 213.5 (112.8–414.5) | 515.0 (344.0–1196.5) | 0.002 * | 192.0 (186.0–1294.0) | 342.0 (215.0–1144.3) | 0.816 |
Na (mmol/L) | 137.0 (129.0–140.0) | 129.5 (125.0–133.8) | 0.222 | 138.0 (135.2–142.5) | 131.0 (128.0–135.0) | 0.056 | 137.0 (135.0–141.5) | 131.0 (123.0–139.0) | 0.022 * |
K (mmol/L) | 4.5 (3.8–5.0) | 5.1 (4.0–6.1) | 0.315 | 3.9 (3.7–4.5) | 4.8 (3.5–5.2) | 0.475 | 3.9 (3.8–4.2) | 4.2 (3.4–6.9) | 0.133 |
Glycemia (mg/dL) | 136 (84.0–158.0) | 125.5 (95.0–125.5) | 1 | 104.0 (94.3–189.0) | 203.0 (111.0–465.0) | 0.027 | 99.0 (93.0–129.3) | 99.0 (86.8–150.5) | 0.675 |
AST (U/L) | 42.5 (28.8–119.0) | 29.5 (21.0–37.6) | 0.056 | 66.0 (36.0–169.0) | 105.0 (95.0–906.0) | 0.043 * | 40.0 (27.0–102.3) | 90.0 (40.0–372.0) | 0.015 * |
ALT (U/L) | 48.5 (19.0–172.0) | 42.5 (33.0–51.6) | 0.949 | 87.0 (33.0–230.0) | 58.0 (57.5–26.0) | 0.327 | 44.0 (24.0–277.0) | 99.0 (14.3–159.0) | 0.576 |
Urea (mg/dL) | 33.0 (30.0–49.0) | 78.5 (26.0–128.6) | 0.610 | 32.0 (18.5–57.0) | 69.0 (30.0–125.5) | 0.004 * | 31.0 (18.0–52.0) | 59.0 (29.5–182.0) | 0.004 * |
Creatinine (mg/dL) | 0.9 (0.7–1.0) | 2.8 (2.7–4.7) | 0.702 | 0.7 (0.6–0.9) | 4.2 (0.7–6.1) | 0.002 * | 0.7 (0.6–1.2) | 1.7 (0.7–3.3) | 0.032 * |
INR | 1.1 (1.1–1.2) | 6.1 (1.4–10.5) | 0.003 * | 1.1 (0.1–1.4) | 1.4 (0.4–1.6) | 0.001 * | 1.0 (0.9–1.0) | 1.1 (1.0–1.2) | 0.000 * |
NLR | 6.3 (2.6–11.5) | 16.6 (13–21.0) | 0.007 * | 5.1 (2.2–8.5) | 16.4 (6.6–18.0) | 0.000 * | 3.7 (2.6–3.9) | 8.8 (6.9–18.0) | 0.001 * |
IIC | 6.5 (2.8–13.9) | 21.7 (19.3–23.9) | 0.003 * | 6.7 (2.6–14.4) | 22.2 (14.6–27.2) | 0.000 * | 4.6 (36.7–43.4) | 13.9 (11.7–21.3) | 0.002 * |
MCVL | 55.9 (39.9–100.6) | 77.2 (74.6–79.8) | 0.445 | 54.8 (45.4–80.7) | 106.9 (98.6–245.1) | 0.000 * | 37.7 (36.7–43.4) | 96.7 (74.7–112.8) | 0.001 * |
Compared Groups | Odd Ratio CI 95% | Relative Risk (RR) of Death | X2 | Df | p Value |
---|---|---|---|---|---|
AP pre-COVID-19 vs. AP during-COVID-19 | 3.54 (1.06–11.77) | 3.00 (1.03–8.74) | 4.667 | 1 | 0.031 * |
AP pre-COVID-19 vs. AP with COVID-19 | 9.75 (2.75–34.46) | 6.00 (2.12–16.91) | 15.441 | 1 | <0.001 * |
AP during-COVID-19 vs. AP with COVID-19 | 2.75 (1.02–7.35) | 2.00 (1.03–3.86) | 4.200 | 1 | 0.040 * |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Rădulescu, P.M.; Căluianu, E.I.; Traşcă, E.T.; Mercuţ, D.; Georgescu, I.; Georgescu, E.F.; Ciupeanu-Călugăru, E.D.; Mercuţ, M.F.; Mercuţ, R.; Padureanu, V.; et al. The Impact of the COVID-19 Pandemic on Outcomes in Acute Pancreatitis: A Propensity Score Matched Study Comparing before and during the Pandemic. Diagnostics 2023, 13, 2446. https://doi.org/10.3390/diagnostics13142446
Rădulescu PM, Căluianu EI, Traşcă ET, Mercuţ D, Georgescu I, Georgescu EF, Ciupeanu-Călugăru ED, Mercuţ MF, Mercuţ R, Padureanu V, et al. The Impact of the COVID-19 Pandemic on Outcomes in Acute Pancreatitis: A Propensity Score Matched Study Comparing before and during the Pandemic. Diagnostics. 2023; 13(14):2446. https://doi.org/10.3390/diagnostics13142446
Chicago/Turabian StyleRădulescu, Patricia Mihaela, Elena Irina Căluianu, Emil Tiberius Traşcă, Dorin Mercuţ, Ion Georgescu, Eugen Florin Georgescu, Eleonora Daniela Ciupeanu-Călugăru, Maria Filoftea Mercuţ, Răzvan Mercuţ, Vlad Padureanu, and et al. 2023. "The Impact of the COVID-19 Pandemic on Outcomes in Acute Pancreatitis: A Propensity Score Matched Study Comparing before and during the Pandemic" Diagnostics 13, no. 14: 2446. https://doi.org/10.3390/diagnostics13142446